相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Small RNAs are modified with N-glycans and displayed on the surface of living cells
Ryan A. Flynn et al.
CELL (2021)
Antibody-independent functions of B cells during viral infections
Vinit Upasani et al.
PLOS PATHOGENS (2021)
The LC3-conjugation machinery specifies the loading of RNA-binding proteins into extracellular vesicles
Andrew M. Leidal et al.
NATURE CELL BIOLOGY (2020)
Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
Abdulaali R. Almutairi et al.
FRONTIERS IN ONCOLOGY (2020)
IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer
Margaux Hubert et al.
SCIENCE IMMUNOLOGY (2020)
Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients
Peng Song et al.
THORACIC CANCER (2020)
Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
Jin-Yu Sun et al.
BIOMARKER RESEARCH (2020)
Natural display of nuclear-encoded RNA on the cell surface and its impact on cell interaction
Norman Huang et al.
GENOME BIOLOGY (2020)
Myeloid Cells during Viral Infections and Inflammation
Ashley A. Stegelmeier et al.
VIRUSES-BASEL (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
The Role of TLRs in Anti-cancer Immunity and Tumor Rejection
Zuzanna Urban-Wojciuk et al.
FRONTIERS IN IMMUNOLOGY (2019)
Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Jean-Charles Cancel et al.
FRONTIERS IN IMMUNOLOGY (2019)
TLR3 Activation of Intratumoral CD103+ Dendritic Cells Modifies the Tumor Infiltrate Conferring Anti-tumor Immunity
Emiliano Roselli et al.
FRONTIERS IN IMMUNOLOGY (2019)
Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens
Jeff DeFalco et al.
CLINICAL IMMUNOLOGY (2018)
Immune-related adverse events of immune checkpoint inhibitors: a brief review
G. Myers
CURRENT ONCOLOGY (2018)
Immune checkpoint inhibitors: recent progress and potential biomarkers
Pramod Darvin et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2018)
The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity
Jan P. Boettcher et al.
TRENDS IN CANCER (2018)
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
Peng-Fei Wang et al.
FRONTIERS IN PHARMACOLOGY (2017)
Endosomal Toll-like receptors inclinically overt and silent autoimmunity
Robert M. Clancy et al.
IMMUNOLOGICAL REVIEWS (2016)
TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function
Thibaud Spinetti et al.
ONCOIMMUNOLOGY (2016)
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
Anne Bertrand et al.
BMC MEDICINE (2015)
Sequencing the functional antibody repertoire-diagnostic and therapeutic discovery
William H. Robinson
NATURE REVIEWS RHEUMATOLOGY (2015)
TLR Signals Induce Phagosomal MHC-I Delivery from the Endosomal Recycling Compartment to Allow Cross-Presentation
Priyanka Nair-Gupta et al.
CELL (2014)
Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors
Hiroaki Shime et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
mRNA is an endogenous ligand for Toll-like receptor 3
K Karikó et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
分享论文
